Redeye has grown more confident in the outlook for BioInvent following i) recent progress for the most important projects as well as ii) the transforming (>SEK 600m) capital raise. Going forward, BioInvent’s transition into a clinical stage immune-oncology player with a broad pipeline should gather momentum, which we argue should drive valuation higher. We raise the base case to SEK 2.8 (2.5).